Syncona Limited Autolus announces closing of public offering (2703W)
April 16 2019 - 1:01AM
UK Regulatory
TIDMSYNC
RNS Number : 2703W
Syncona Limited
16 April 2019
Syncona Limited
Autolus announces closing of public offering
16 April 2019
Syncona Ltd, a leading healthcare company focused on founding,
building and funding global leaders in life science, notes that its
portfolio company, Autolus Therapeutics plc ("Autolus") has
announced the closing of its previously announced underwritten
public offering in the United States of 4,830,000 American
Depositary Shares ("ADSs") representing 4,830,000 ordinary shares,
at a public offering price of $24.00 per ADS, which includes an
additional 630,000 ADSs issued upon the exercise in full of the
underwriters' option to purchase additional ADSs. Aggregate net
proceeds to Autolus, after underwriting discounts but before
estimated offering expenses, were $109.0 million. All of the ADSs
were offered by Autolus.
Syncona agreed to invest $24 million (GBP18.3 million[1]) in the
offering. Following the offering, Syncona retains a stake of 30.0%
in Autolus (amounting to 14,592,098 ordinary shares) which was
valued at GBP311.8 million at close of business on 15 April
2019.
The offering was made only by means of a prospectus. The final
prospectus related to the offering was filed with the U.S.
Securities and Exchange Commission (the "SEC"). Copies of the final
prospectus can be obtained from either of the joint book-running
managers for the offering, Goldman Sachs & Co. LLC, Attention:
Prospectus Department, 200 West Street, New York, NY 10282, or by
telephone at +1 866 471 2526 or by email at
Prospectus-ny@ny.email.gs.com; or Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New
York, NY 10022, or by telephone at + 1 877 821 7388 or by email at
Prospectus_Department@Jefferies.com. For the avoidance of doubt,
such prospectus will not constitute a "prospectus" for the purposes
of Directive 2003/71/EC (and amendments thereto, including
Directive 2010/73/EU, to the extent implemented in each relevant EU
member state) and will not have been reviewed by any competent
authority in any EU member state.
A registration statement on Form F-1 relating to these
securities was declared effective by the SEC on April 10, 2019. The
registration statement can be accessed through the SEC's website at
www.sec.gov. This press release does not constitute an offer to
sell or the solicitation of an offer to buy securities, and shall
not constitute an offer, solicitation or sale in any jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of that
jurisdiction.
[ENDS]
Enquiries
Syncona Ltd
Annabel Clay / Siobhan Weaver
Tel: +44 (0) 20 3981 7940
FTI Consulting
Brett Pollard / Natalie Garland-Collins
Tel: +44 (0) 20 3727 1000
Forward-looking statements - this announcement contains certain
forward-looking statements with respect to the portfolio of
investments of Syncona Ltd. These statements and forecasts involve
risk and uncertainty because they relate to events and depend upon
circumstances that may or may not occur in the future. There are a
number of factors that could cause actual results or developments
to differ materially from those expressed or implied by these
forward-looking statements and forecasts. Nothing in this
announcement should be construed as a profit forecast.
About Syncona
Syncona is a leading FTSE250 healthcare company focused on
founding, building and funding global leaders in life science. Our
vision is to deliver transformational treatments to patients in
truly innovative areas of healthcare while generating superior
returns for shareholders.
We seek to partner with the best, brightest and most ambitious
minds in science to build globally competitive businesses.
We take a long-term view, underpinned by a deep pool of capital,
and are established leaders in gene and cell therapy. We focus on
delivering dramatic efficacy for patients in areas of high unmet
need
About Autolus
Autolus is a biopharmaceutical company developing
next-generation programmed T cell therapies for the treatment of
cancer.
[1] As at 15 April 2019
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
PFUEAELSFAKNEAF
(END) Dow Jones Newswires
April 16, 2019 02:01 ET (06:01 GMT)
Syncona (LSE:SYNC)
Historical Stock Chart
From Apr 2024 to May 2024
Syncona (LSE:SYNC)
Historical Stock Chart
From May 2023 to May 2024